Recent

% | $
Quotes you view appear here for quick access.

Celldex Therapeutics, Inc. Message Board

whippersnapper65 321 posts  |  Last Activity: 7 hours ago Member since: Jun 20, 2009
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Someone bought 37200 in AH at $28.36

    by weightbayou Apr 20, 2015 5:21 PM
    whippersnapper65 whippersnapper65 Apr 20, 2015 5:33 PM Flag

    It's high past time for $30 pps to be in the rear view mirror forever, fading into the horizon behind us as we drive forward.

    Sentiment: Strong Buy

  • whippersnapper65 whippersnapper65 Apr 20, 2015 4:11 PM Flag

    The abstracts will be released on May 13 at 5:00 p.m. E.T. by ASCO. If the ReACT data weren't final by the time the abstract was submitted, then Celldex should issue a P.R. on May 13 stating that final, updated data will be presented during the symposium on May 31 and that a P.R. containing the final results will be released on the company website concurrent with the presentation's start time.

    Sentiment: Strong Buy

  • A Saturday poster session featuring Glemba in METRIC and a Sunday symposium featuring Rintega in ReACT:

    Saturday, May 30 | 8:00 AM - 11:30 AM
    Breast Cancer—Triple-Negative/Cytotoxics/Local Therapy
    Session Type: Poster Session
    Track(s): Breast Cancer
    Presentation(s):
    Abstract #TPS1110
    METRIC: A randomized international study of the antibody-drug conjugate glembatumumab vedotin (GV or CDX-011) in patients (pts) with metastatic gpNMB-overexpressing triple-negative breast cancer (TNBC).
    Denise A. Yardley, MD
    Sarah Cannon Research Institute/Tennessee Oncology, PLLC


    Sunday, May 31 | 8:00 AM - 9:30 AM
    Immunotherapy for Central Nervous System Tumors: Biomarkers and Novel Data
    Session Type: Clinical Science Symposium
    Track(s): Central Nervous System Tumors
    Presentation(s):
    Abstract #2009
    8:00 AM - 8:12 AM
    ReACT: Overall survival from a randomized phase II study of rindopepimut (CDX-110) plus bevacizumab in relapsed glioblastoma.
    David A. Reardon, MD
    Dana-Farber Cancer Institute

    Sentiment: Strong Buy

  • Reply to

    From MF today...

    by neshua202 Apr 20, 2015 10:33 AM
    whippersnapper65 whippersnapper65 Apr 20, 2015 11:07 AM Flag

    Well, a $60 share price would be above my floor of $40, so it's not really a disagreement. I would agree with you in this: that full approval of Rintega (coming soon) plus the discounted future value of Glemba and Varli would set the floor at $60 pps. Yes, a $60 minimum pps is on the horizon.

    Sentiment: Strong Buy

  • Reply to

    From MF today...

    by neshua202 Apr 20, 2015 10:33 AM
    whippersnapper65 whippersnapper65 Apr 20, 2015 10:52 AM Flag

    I sure as hell was smarter than the market when I bought thousands of shares below $4, and I'm smarter than the market now on this particular stock. Be advised: $30 pps for CLDX will eventually look like $4 looks now.

    Sentiment: Strong Buy

  • Reply to

    From MF today...

    by neshua202 Apr 20, 2015 10:33 AM
    whippersnapper65 whippersnapper65 Apr 20, 2015 10:39 AM Flag

    Yes, Neshua: the market doesn't understand Varli nor its potential. For that reason, the market doesn't understand that Celldex should have a valuation at least 50% higher than it currently has as a minimum, as a floor beneath which the share price should never trade.

    Sentiment: Strong Buy

  • whippersnapper65 whippersnapper65 Apr 20, 2015 9:57 AM Flag

    Frank, my man, read the whole thread and then I think you'll get the joke that seems to have gone over your head due to a lack of context.

  • Strong correlation between shorts posting negative comments and red-thumbing positive posts following positive Varli announcements.

    Sentiment: Strong Buy

  • Reply to

    This will be talk about at ASCO

    by grey3840 Apr 20, 2015 8:56 AM
    whippersnapper65 whippersnapper65 Apr 20, 2015 9:13 AM Flag

    And it ought to be the talk of oncology and immunotherapy bigwigs until one of two things happen: Varli is approved or Celldex is bought out after an intense bidding war.

    Sentiment: Strong Buy

  • Higher and higher!

    Sentiment: Strong Buy

  • whippersnapper65 whippersnapper65 Apr 19, 2015 1:06 AM Flag

    I believe the patent for targeting EGFRviii is owned by Dr. Sampson and Dr. Mitchell at Duke University. I also believe that Celldex has an exclusive license to the patent for creating EGFRviii targeting vaccines, and that royalties would be paid to Duke upon reaching the milestone of commercialization.

    Sentiment: Strong Buy

  • whippersnapper65 whippersnapper65 Apr 17, 2015 9:46 PM Flag

    And why would a lawyer worth his salt who has at least eight years of such experience agree to leave his comfortable and lucrative and successful job to work at Celldex unless the prospects at Celldex were much, much better? Job applicants will want to know how likely Celldex's prospects are for reaching commercialization, and management will confidently be able to assure qualified applicants that the prospects are outstanding. Nobody is going to leave a successful career for Celldex unless he knows that he can do even better at Celldex for the long haul.

    Sentiment: Strong Buy

  • whippersnapper65 whippersnapper65 Apr 17, 2015 7:27 PM Flag

    Yes, the writing is on the wall that Rintega is going to be granted early approval and that patients in the Glemba trials are doing so well that Glemba's approval is highly likely.

    Marucci has been assembling a sales staff for Rintega, creating and hiring for new positions directly related to commercial activity as opposed to merely clinical research, and ensuring that the company has ample funds to expand into commercialization without hampering the already robust research activity being conducted in early-stage treatments.

    You simply do not create and hire for the types of jobs that Celldex has been advertising unless commercial launch is expected within a short timeframe.

    The final ReACT data that will be presented at ASCO will be so compelling that the FDA will grant early approval for Rintega for use in relapsed patients. First-line use might not be far behind. I believe there's a decent chance that the IDMC will halt ACT-IV early for efficacy at the first interim look, which will happen within the next few months.

    Sentiment: Strong Buy

  • whippersnapper65 whippersnapper65 Apr 17, 2015 4:19 PM Flag

    Must have been some big block exchanges at the close. The volume wasn't anywhere near that just before the closing bell.

  • whippersnapper65 whippersnapper65 Apr 17, 2015 4:17 PM Flag

    For a while it was showing 26.99. The trading was highly erratic in the final ten minutes.

  • Reply to

    Superior results for Opdivo....

    by cldxlong Apr 17, 2015 1:04 PM
    whippersnapper65 whippersnapper65 Apr 17, 2015 3:37 PM Flag

    Watch the same thing happen with Rindo in ACT-IV this summer.

    Sentiment: Strong Buy

  • whippersnapper65 by whippersnapper65 Apr 17, 2015 10:37 AM Flag

    Go away from the computer for the rest of the trading day. I suspected they might make the 28 calls worthless, but they've even succeeded in making the 27 calls worthless at this point.

    All games. All manipulation. We've seen this numerous times before, almost like clockwork for options expiration.

    Wait for Monday, when ASCO abstracts are released.

    If you hold or buy here, you'll be able to sell at a much higher price later this year, and probably this summer.

    Sentiment: Strong Buy

  • There are reports coming out that one of the reasons Hillary Clinton wiped her private email server clean is because there were numerous emails to and from and referencing her many lesbian consorts over the years, some of whom are public figures and none of whom she wants exposed.

    With her presidential campaign off to a lousy start and sinking quickly, Hillary might just be desperate enough to play the lesbian card in order to guilt Democrats into voting for her and to spin opposition to her into an expression of anti-gay sentiment.

    Yes, the reports are coming from the National Enquirer. But consider that the Enquirer has more credibility than Rolling Stone, which made up a story about fraternity gang rape out of whole cloth.

  • whippersnapper65 by whippersnapper65 Apr 16, 2015 11:27 AM Flag

    (With apologies to Schoolhouse Rock.)

    Manipulation, what's your function?
    Triggering all the stops I can harvest.
    Manipulation, what's your function?
    Taking more shares from weak-handed retail.

    Sentiment: Strong Buy

  • ASCO abstract titles and program information about sessions and speakers will be available on Monday.

    Management has stated that it expects to present final ReACT data at ASCO. I'm eager to know what the presentation forum will be. I'm also eager to know what other treatments in Celldex's pipeline will have a presence at ASCO.

    If ReACT is going to be featured prominently, there ought to be a company PR issued early next week stating so.

    Shorts, you'd better cover. April options expire at the end of this week. If those are suppressing the share price now, they won't be doing so on Monday, a day on which your short position could blow up in your hands. The chart is signaling a high likelihood of an imminent bullish breakout. Good news about ASCO would accelerate and intensify the rally.

    Sentiment: Strong Buy

CLDX
27.80+0.66(+2.43%)May 22 4:00 PMEDT